NEXGEL (NXGL) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
23 Apr, 2026Executive summary
Revenue for 2025 was $11.4 million, up 31.5% year-over-year, driven by growth in branded consumer products, especially following the Silly George acquisition in May 2024.
Gross profit increased to $4.5 million (39.5% margin), compared to $2.7 million (31.6% margin) in 2024.
Net loss attributable to stockholders was $3.0 million, an improvement from a $3.3 million loss in 2024.
The company continues to focus on expanding its consumer product portfolio and contract manufacturing business, with ongoing investments in product development and strategic acquisitions.
Financial highlights
Revenues: $11.4 million in 2025 vs. $8.7 million in 2024 (+31.5%).
Gross profit: $4.5 million (39.5% margin) in 2025 vs. $2.7 million (31.6% margin) in 2024.
Net loss: $3.0 million in 2025 vs. $3.3 million in 2024.
Cash and equivalents at year-end: $317,000, with $741,000 in restricted cash.
Working capital: $1.4 million at December 31, 2025, down from $2.6 million in 2024.
No customer accounted for more than 10% of revenue in 2025 or 2024.
Outlook and guidance
Management expects continued near-term losses but is focused on expanding sales channels, developing new products, and pursuing strategic acquisitions.
Additional capital raises through debt or equity may be necessary to support growth and acquisitions.
The company aims to achieve long-term profitability through growth in consumer products and contract manufacturing.
Latest events from NEXGEL
- Acquisition and partnership triple revenue, drive profitability, and expand into regenerative medicine.NXGL
M&A announcement21 Apr 2026 - Hydrogel innovation and strategic partnerships fuel rapid growth and expanding product lines.NXGL
Planet MicroCap Showcase: VEGAS 20253 Feb 2026 - Record Q2 revenue and strong outlook driven by branded products and Silly George growth.NXGL
Q2 20242 Feb 2026 - Q3 revenue up 141% to $2.94M, gross margin 43.6%, but losses and risks persist.NXGL
Q3 202414 Jan 2026 - Strong growth from product innovation, acquisitions, and major partnerships, with profitability in focus.NXGL
IAccess Alpha–Buyside Best Ideas Winter Virtual Conference 202411 Jan 2026 - Record revenue growth and improved margins set stage for positive EBITDA in 2025.NXGL
Q4 202424 Dec 2025 - Shareholders will vote on director elections, incentive plan expansion, and executive pay, all backed by the Board.NXGL
Proxy Filing2 Dec 2025 - Vote to increase authorized common stock to 1B shares for future flexibility is recommended.NXGL
Proxy Filing2 Dec 2025 - Q1 2025 revenue up 121%, margin at 42.4%, and positive EBITDA targeted for 2025.NXGL
Q1 202527 Nov 2025